Novel Quinazoline Moiety: Synthesis, In-Vitro Biological Evaluation and Molecular Modelling Studies
DOI:
https://doi.org/10.63682/jns.v14i32S.7426Keywords:
EGFR, quinazoline, competitive inhibitor, covalent inhibitor, allosteric inhibitorAbstract
The quinazoline core has emerged as a favorable scaffold for the development of novel EGFR inhibitors due to increased affinity for the active site of EGFR kinase. Currently, there are five first-generation (gefitinib, erlotinib, lapatinib, vandetanib) and two second-generation (afatinib and dacomitinib) quinazoline-based EGFR inhibitors approved for the treatment of various types of cancers. The aim of this review is to outline the structural modulations favorable for the inhibitory activity toward both common mutant (del19 and L858R) and resistance-conferring mutant (T790M and C797S) EGFR forms, and provide an overview of the newly synthesized quinazoline derivatives as potentially competitive, covalent or allosteric inhibitors of EGFR
Downloads
Metrics
References
Australian Institute of Health and Welfare 2017.
Parkin DM, Stjernswo¨rd J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull WHO 1984;62:163–182
Parkin DM, Bray F, Devesa S. Cancer burden in the year 2000: the global picture. Eur J Cancer2001;37:S4 –S66.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. Lyon, France: International Agency for Research on Cancer; 2001.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 Version 2.0. Lyon, France: IARCPress; 2004.
Pisani P, Bray F, Parkin DM. Estimates of the worldwide prevalence of cancer for 25 cancers in the adult population. Int J Cancer 2002;97:72– 81.
Pisani P, Parkin DM, Bray Fl, Ferlay J. Estimates of the worldwide mortality from twenty five major cancers in 1990. Implications for prevention, and projections of future burden. Int J Cancer 1999;83:18 –29.
C.J. Tsai, R. Nussinov, The molecular basis of targeting protein kinases in cancer therapeutics, Semin. Cancer Biol. 23 (2013) 235e242.
Eckhardt, S. Curr. Med. Chem. Anti-Cancer Agents 2002, 2, 419.
Lee, C. W.; Hong, D. H.; Han, S. B.; Jong, S. H.; Kim, H. C.; Fine, R. L.; Lee, S. H.; Kim, H. M. Biochem. Pharmacol. 2002, 64, 473.
Asai N, Aoshima M, Ohkuni Y, Otsuka Y, Kaneko N Indian J Palliat Care. 2012 Jan; 18(1):40-4.
S. Singhal, B.S. Chakraborty, Signal Detection of Docetaxel in Canadian Spontaneous Adverse Event Reports, J. Pharm. Res., (2012), Vol. 5, Issue 2, 1070.
G.F. Macri, A. Greco, A. Gallo, M. Fusconi, M.D. Caterina Marinelli, M.D.
Vincentiis, Use of electrochemotherapy in a case of neck skin metastasis of oral
squamous cell carcinoma: Case report and considerations, Head & Neck, 36 (2014) E86-E90.
M. Mubeen, S.G. Kini, A Review on: The Design and Development of EGFR
Tyrosine Kinase Inhibitors in Cancer Therapy, Int. J. Ther. Appl., 5(2012)29-37.
C. Com, Targeted Cancer Therapies : Answers to Your Questions, Targeted Cancer
Therapies Answers to Your Questions. Source: www.cancer.gov.
Y. Kawakita, K Miwa, M. Seto, H. Banno, Y. Ohta, T. Tamura, T. Yusa, H. Miki, H. Kamiguchi, Y. Ikeda, T. Tanaka, K. Kamiyama, T. Ishikawa, Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy, Bioorg. Med. Chem., 20 (2012) 6171-6180. Jemal et al. 2011; Siegel et al. 2016 Singh et al. 2018
P.N. Dube, M.N. Waghmare, S.N. Mokale, Chem. Biol. Drug Des. 87 (2016) 608. H.A. Bhuvaa, S.G.J. Kinib, Mol. Graph. Mod. 29 (2010) 32.
M.K. Hussain, M.I. Ansari, N. Yadav, P.K. Gupta, A.K. Gupta, R. Saxena, I. Fatim, M. Manohar, P. Kushwaha, V. Khedgikar, J. Gautam, R. Kant, P.R. Maulik, R. Trivedi, A. Dwivedi, K.R. Kumar, A.K. Saxena, K. Hajela, RSC Adv. 4 (2014) 8828.
E. Zwick, J. Bange, A. Ullrich, Endocr. Relat. Cancer 8 (2001) 161.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016, CA: a cancer journal for clinicians, 66 (2016) 7-30.
WHO, Cancer, fact sheet, 2018, 2018. http://www.who.int/news- room/factsheets/ detail/cancer. (Accessed September 2018).
F. Bray, A. Jemal, N. Grey, J. Ferlay, D. Forman, Global cancer transitions
according to the Human Development Index (2008–2030): a population- based study, The lancet oncology, 13 (2012) 790-801.
E. Christie, D. Bowtell, Acquired chemotherapy resistance in ovarian cancer, Annals of Oncology, 28 (2017) viii13-viii15.
GLOBOCAN 2012, http://globocan.iarc.fr/Default.aspx.
M. J. Thun, J. O. DeLancey, M. M. Center, A. Jemal, and E. M. Ward, “The global burden of cancer: priorities for prevention,” Carcinogenesis, vol. 31, no. 1, pp. 100–110, 2009.
Cancer facts and figure 2017: (https://www.cancer.org/research/cancer-facts-statistics/allcancer- facts-figures/cancer-facts-figures-2017.html
Harris C C, Hollstein M. Clinical Implications of the p53 Tumor- Suppressor Gene New Eng J Med 1993; 329: 1318-1327.
P. Griess, Ueber die einwirkung des cyans auf anthranilsaure, Berichte 2 (1869) 415-418.
P. Griess, Ueber die einwirkung von cyan auf amidobenzoesaure und anthranilsaure in wasserigerlosung, Berichte 11 (1878) 1985-1988.
(a) Zhang, Y.; Wang, P.Y.; Hu, D.Y.; Jin, L.H.; Yang, S. Research progress on quinazoline derivatives with epidermal growth factor receptor inhibiting bioactivity. Chin. J. Org. Chem., 2012, 32, 444- 461. (b) Li, D.D.; Hou, Y.P.; Wang, W.; Zhu, H.L. Exploration of chemical space based on 4- nilinoquinazoline. Curr. Med. Chem.,2012, 19, 871-892.
Honkanen, E.; Pippuri, A.; Kairisalo, P.; Nore, P.; Karppanen, H.; Paakkari, I. J. Med. Chem. 1983, 26, 1433.
Al-Omar, M. A.; El-Azab, A. S.; El-Obeid, H. A.; Abdel Hamide, S. G. J. Saudi Chem. Soc. 2006, 10, 113.
S. Malik, R.S. Bahare, S.A. Khan, Design, synthesis and anticonvulsant evaluation of N-(benzo[d] thiazol-2-ylcarbamoyl)-2-methyl-4- oxoquinazoline-3(4H) carbothioamide derivatives: A hybrid pharmacophore approach, Eur J Med Chem, 67 (2013) 1-13.
G. Ji, D. Yang, X. Wang, C.Y. Chen, Q. Deng, Z.Q. Ge, L.J. Yuan, X.L. Yang, F. Liao, Design, synthesis and evaluation of novel quinazoline-2,4- dione derivatives as chitin synthase inhibitors and antifungal agents, Bioorgan Med Chem, 22 (2014) 3405-3413.
A.M. Alafeefy, A.A. Kadi, O.A. Al-Deeb, K.E.H. El-Tahir, N.A. Al-Jaber, Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives, Eur J Med Chem, 45 (2010) 4947-4952.
Ali, Z.; Akhtar, M.J.; Haider, M.R.; Khan, A.A.; Siddiqui, A.A.; Yar, M.S. Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor. Bioorg. Chem. 2017, 71, 181–191.
T.P. Selvam, A. Sivakumar, P.P. Prabhu, Design and synthesis of quinazoline carboxylates against Gram-positive, Gram-negative, fungal pathogenic strains, and Mycobacterium tuberculosis, J. Pharm. BioAllied Sci. 6 (2014) 278-284.
R. Al-Salahi, H.A. Abuelizz, H.A. Ghabbour, R. El-Dib, M. Marzouk, Molecular docking study and antiviral evaluation of 2-thioxo- benzo[g]quinazolin- 4(3H)-one derivatives, Chem. Cent. J. 19 (2016) 10e21.
Z. Wan, D. Hu, P. Li, D. Xie, X. Gan, Synthesis, antiviral bioactivity of novel 4- thioquinazoline derivatives containing chalcone moiety, Molecules 20 (2015) 11861e11874.
S. Ravez, O. Castillo-Aguilera, P. Depreux, L. Goossens, Quinazoline derivatives as anticancer drugs: a patent review (2011-present), Expert Opin. Ther. Pat. 25 (2015) 789e804.
S. Mehndiratta, S. Sapra, G. Singh, M. Singh, K. Nepali, Quinazolines as apoptosis inducers and inhibitors: a review of patent literature, Recent Pat. Anti-Cancer Drug Discov. 11 (2016) 2-66.
K. Saurav, M. Garima, S. Pradeep, K. K. Jha, R. L. Khosa, and S. K. Gupta, “Quinazoline-4-one: a highly important hetrocycle with diverse biological activities,”DerChemicaSinica, vol. 2, no. 4, pp. 36–58, 2011.
(a) Chen, J.H.; Luo, Y.Z.; Wang, W.; Zhou, W.W.; Wen, X.P. A phase III study on icotinib hydrochloride for non-small cell lung cancer. Anti-tumor Pharm., 2011, 1, 441-443. (b) Gu, A.Q.; Shi, C. L.; Xiong, L.W.; Chu, T.Q.; Jun, P.; Han, B.H. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin. J. Cancer Res., 2013, 25, 90-94.
Z.J. Long, J. Xu, M. Yan, J.G. Zhang, Z. Guan, D.Z. Xu, X.R. Wang, J.N. Yao, F.M. Zheng, G.L. Chu, J.X. Cao, Y.X. Zeng, Q.T. Liu, ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three- dimensional culture, Cell Cycle, 7 (2008) 1473-1479.
A.A. Mortlock, K.M. Foote, N.M. Heron, F.H. Jung, G. Pasquet, J.J.M. Lohmann, N. Warin, F. Renaud, C. De Savi, N.J. Roberts, T. Johnson, C.B. Dousson, G.B. Hill, D. Perkins, G. Hatter, R.W. Wilkinson, S.R. Wedge, S.P. Heaton, R. Odedra, N.J. Keen, C. Crafter, E. Brown, K. Thompson, S. Brightwell, L. Khatri, M.C. Brady, S. Kearney, D. McKillop, S. Rhead, T. Parry, S. Green, Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase, J Med Chem, 50 (2007) 2213-2224.
J.A. McIntyre, J. Castaner, P.A. Leeson, Canertinibdihydrochloride - Oncolytic drug HER (ErbB) inhibitor, Drug Future, 30 (2005) 771-779.
Zayed, M.F.; Hassan, M.H. Design, synthesis and biological evaluation studies of novel quinazoline derivatives as cytotoxic agents. Drug Res. 2013, 63, 210–215.
Zayed, M.F.; Ahmed, H.E.A.; Ihmaid, S.; Omar, A.M.; Abdelrahim, A.S. Synthesis and screening of some new fluorinated quinazolinone-sulphonamide hybrids as anticancer agents. J. Taibah Univ. Med. Sci. 2015, 10, 333–339.
Layevaa, A.A.; Nosovaa, E.V.; Lipunovaa, G.N.; Trashakhovaa, T.V.; Charushinb, V.N. A new approach to fluorinated 4(3H)-quinazolinones. J. Fluor. Chem. 2007, 128, 748–754.
Ihmaid, S.; Ahmed, H.E.A.; Zayed, M.F. The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization. Int. J. Mol. Sci. 2018, 19, 408.
"Antimicrobial". Merriam-Webster Online Dictionary. Archived from the original on 24 April 2009. Retrieved 2009-05-02.
"Antimicrobial Porous Media | Microbicidal Technology | Porex Barrier Technology". www.porex.com. Retrieved 2017-02-16.
M. Gainet *, E. Guardiola, A. Dufresne, X. Pivot “The Epidermal Growth Factor receptors (EGFR): a new target for anticancer therapy” 7 (2003) 195–199.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
